Matches in SemOpenAlex for { <https://semopenalex.org/work/W4295258044> ?p ?o ?g. }
Showing items 1 to 64 of
64
with 100 items per page.
- W4295258044 endingPage "AB110" @default.
- W4295258044 startingPage "AB110" @default.
- W4295258044 abstract "Background: Lifetime incidence of nail psoriasis in patients with moderate-to-severe psoriasis (PsO) is 80-90%, and up to 55% of patients have nail psoriasis at any given time. Nail psoriasis is even more prevalent in patients with psoriatic arthritis (PsA). Complete psoriasis clearance is an achievable therapeutic goal, and ideally should include resolution of psoriasis within nails. Here, we assessed simultaneous skin and nail clearance in patients with psoriasis across 5 head-to-head trials comparing ixekizumab with other biologics. Methods: Data were assessed in patients with PsO (with or without PsA) with nail psoriasis at baseline from the IXORA-R, IXORA-S, UNCOVER-2, UNCOVER-3, and SPIRIT-H2H trials. IXE patients received IXEQ2W to week 12, and IXEQ4W beyond week 12. Complete skin improvement was assessed by PASI 100, and complete nail resolution was assessed by either PGA-F (0) (IXORA-R) or NAPSI (0) (all other trials). Treatment comparisons were evaluated using the Cochran Mantel Haenszel test. Nonresponder imputation was used for missing data. Results: Ixekizumab achieved numerically greater simultaneous skin and nail clearance than etanercept (UNCOVER-2: ixekizumab = 6.8%, etanercept = 0.4%, P < .001, UNCOVER-3: ixekizumab = 10.5%, etanercept = 0.8%, P < .001) at 12 weeks; guselkumab (ixekizumab = 37.9%, guselkumab = 28.0%, P = .079), ustekinumab (ixekizumab = 28.6%, ustekinumab = 8.6%, P < .001), and adalimumab (ixekizumab = 45.9%, adalimumab = 17.1%, P = .006) at 24 weeks; and ustekinumab (ixekizumab = 40.5%, ustekinumab = 16.2%, P < .001), and adalimumab (ixekizumab = 51.4%, adalimumab = 22.0%, P = .007) at 52 weeks. Conclusions: Across five head-to-head trials, ixekizumab-treated patients had higher rates of simultaneous complete skin and nail clearance compared with etanercept, guselkumab, ustekinumab and adalimumab, thereby reinforcing ixekizumab’s ability to achieve high levels of efficacy." @default.
- W4295258044 created "2022-09-12" @default.
- W4295258044 creator A5020923397 @default.
- W4295258044 creator A5025545596 @default.
- W4295258044 creator A5080237247 @default.
- W4295258044 date "2022-09-01" @default.
- W4295258044 modified "2023-09-23" @default.
- W4295258044 title "32827 Simultaneous nail and skin clearance in 5 ixekizumab head-to-head trials for moderate-to-severe psoriasis and psoriatic arthritis" @default.
- W4295258044 doi "https://doi.org/10.1016/j.jaad.2022.06.472" @default.
- W4295258044 hasPublicationYear "2022" @default.
- W4295258044 type Work @default.
- W4295258044 citedByCount "0" @default.
- W4295258044 crossrefType "journal-article" @default.
- W4295258044 hasAuthorship W4295258044A5020923397 @default.
- W4295258044 hasAuthorship W4295258044A5025545596 @default.
- W4295258044 hasAuthorship W4295258044A5080237247 @default.
- W4295258044 hasConcept C126322002 @default.
- W4295258044 hasConcept C142724271 @default.
- W4295258044 hasConcept C16005928 @default.
- W4295258044 hasConcept C204787440 @default.
- W4295258044 hasConcept C27081682 @default.
- W4295258044 hasConcept C2776260265 @default.
- W4295258044 hasConcept C2777226972 @default.
- W4295258044 hasConcept C2777575956 @default.
- W4295258044 hasConcept C2778975655 @default.
- W4295258044 hasConcept C2779745271 @default.
- W4295258044 hasConcept C2779786854 @default.
- W4295258044 hasConcept C2780132546 @default.
- W4295258044 hasConcept C2780564577 @default.
- W4295258044 hasConcept C71924100 @default.
- W4295258044 hasConceptScore W4295258044C126322002 @default.
- W4295258044 hasConceptScore W4295258044C142724271 @default.
- W4295258044 hasConceptScore W4295258044C16005928 @default.
- W4295258044 hasConceptScore W4295258044C204787440 @default.
- W4295258044 hasConceptScore W4295258044C27081682 @default.
- W4295258044 hasConceptScore W4295258044C2776260265 @default.
- W4295258044 hasConceptScore W4295258044C2777226972 @default.
- W4295258044 hasConceptScore W4295258044C2777575956 @default.
- W4295258044 hasConceptScore W4295258044C2778975655 @default.
- W4295258044 hasConceptScore W4295258044C2779745271 @default.
- W4295258044 hasConceptScore W4295258044C2779786854 @default.
- W4295258044 hasConceptScore W4295258044C2780132546 @default.
- W4295258044 hasConceptScore W4295258044C2780564577 @default.
- W4295258044 hasConceptScore W4295258044C71924100 @default.
- W4295258044 hasIssue "3" @default.
- W4295258044 hasLocation W42952580441 @default.
- W4295258044 hasOpenAccess W4295258044 @default.
- W4295258044 hasPrimaryLocation W42952580441 @default.
- W4295258044 hasRelatedWork W1970925217 @default.
- W4295258044 hasRelatedWork W2007444191 @default.
- W4295258044 hasRelatedWork W2140061052 @default.
- W4295258044 hasRelatedWork W2766755230 @default.
- W4295258044 hasRelatedWork W2901240458 @default.
- W4295258044 hasRelatedWork W2984218665 @default.
- W4295258044 hasRelatedWork W4213351251 @default.
- W4295258044 hasRelatedWork W4248008924 @default.
- W4295258044 hasRelatedWork W4324149340 @default.
- W4295258044 hasRelatedWork W71416396 @default.
- W4295258044 hasVolume "87" @default.
- W4295258044 isParatext "false" @default.
- W4295258044 isRetracted "false" @default.
- W4295258044 workType "article" @default.